China Shineway Pharmaceutical Group Limited (2877) Price & Analysis

Compare

0 Followers

2877 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$7.14 - HK$10.76

Previous CloseN/A

Volume914.00K

Average Volume (3M)1.51M

Market Cap

HK$5.73B

Enterprise ValueHK$751.47M

Total Cash (Recent Filing)¥3.61B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)6.3

Beta0.61

Next Earnings

Sep 02, 2025

EPS EstimateN/A

Next Dividend Ex-Date

Apr 30, 2025

Dividend Yield7.65%

Share Statistics

EPS (TTM)1.21

Shares Outstanding827,000,000

10 Day Avg. Volume2,008,432

30 Day Avg. Volume1,507,080

Financial Highlights & Ratios

PEG Ratio0.27

Price to Book (P/B)N/A

Price to Sales (P/S)1.40

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

---

China Shineway Pharmaceutical Group Limited News

PremiumDividends

China Shineway Pharmaceutical Group Limited (2877) Announces Q2 Dividend: Read On for Important Dates

14d ago

2877

PremiumCompany Announcements

China Shineway Announces Interim Dividend for FY2025

17d ago

2877

PremiumCompany Announcements

China Shineway Reports 2024 Revenue Decline Amid TCM Industry Challenges

17d ago

2877

PremiumCompany Announcements

China Shineway Pharmaceutical Schedules Board Meeting for Annual Results and Dividend Consideration

27d ago

2877

PremiumCompany Announcements

China Shineway Reports Turnover Decline Amid Product Sales Drop

5M ago

2877

PremiumCompany Announcements

China Shineway Posts Higher Profits Amid Sales Dip

8M ago

2877

PremiumCompany Announcements

China Shineway Declares Mid-Year Dividend

8M ago

2877

PremiumCompany Announcements

China Shineway Prepares to Discuss Interim Results

8M ago

2877

See All HK:2877 News

---

Financials

Quarterly

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

1.72%

Mutual Funds

― Other Institutional Investors

96.43% Public Companies and

Individual Investors

Detailed Ownership Overview >

2877 FAQ

What was China Shineway Pharmaceutical Group Limited’s price range in the past 12 months?

China Shineway Pharmaceutical Group Limited lowest stock price was HK$7.14 and its highest was HK$10.76 in the past 12 months.

What is China Shineway Pharmaceutical Group Limited’s market cap?

China Shineway Pharmaceutical Group Limited’s market cap is HK$5.73B.

When is China Shineway Pharmaceutical Group Limited’s upcoming earnings report date?

China Shineway Pharmaceutical Group Limited’s upcoming earnings report date is Sep 02, 2025 which is in 141 days.

How were China Shineway Pharmaceutical Group Limited’s earnings last quarter?

China Shineway Pharmaceutical Group Limited released its earnings results on Mar 28, 2025. The company reported HK$0.307 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.307.

Is China Shineway Pharmaceutical Group Limited overvalued?

According to Wall Street analysts China Shineway Pharmaceutical Group Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does China Shineway Pharmaceutical Group Limited pay dividends?

China Shineway Pharmaceutical Group Limited pays a Annually dividend of HK$0.384 which represents an annual dividend yield of 7.65%. See more information on China Shineway Pharmaceutical Group Limited dividends here

What is China Shineway Pharmaceutical Group Limited’s EPS estimate?

China Shineway Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does China Shineway Pharmaceutical Group Limited have?

China Shineway Pharmaceutical Group Limited has 827,000,000 shares outstanding.

What happened to China Shineway Pharmaceutical Group Limited’s price movement after its last earnings report?

China Shineway Pharmaceutical Group Limited reported an EPS of HK$0.307 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -8.314%.

Which hedge fund is a major shareholder of China Shineway Pharmaceutical Group Limited?

Currently, no hedge funds are holding shares in HK:2877

---

China Shineway Pharmaceutical Group Limited Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

11.61%

Trailing 12-Months

Asset Growth

1.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

China Shineway Pharmaceutical Group Limited

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.

---

2877 Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2022","6":"Nov<br/>2022","9":"Feb<br/>2023","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.64,8.89846153846154,8.156923076923077,7.415384615384616,6.673846153846155,5.932307692307693,5.190769230769231,4.44923076923077,3.707692307692308,2.966153846153846,2.224615384615385,1.4830769230769238,0.741538461538461,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.35,"date":1651363200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.09,"date":1654041600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.81,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.15,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.06,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.31,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.28,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.29,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.72,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.45,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.17,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.17,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Sino Biopharmaceutical

―

CHJTF

CSPC Pharmaceutical Group

―

SFOSF

Shanghai Fosun Pharmaceutical (Group) Co

―

640

China Resources Pharmaceutical Group Ltd.

―

CL4

Huazhu Group Ltd

―

Compare HK:2877 Stocks >

Best Analysts Covering 2877

1 Year

Chris LuiJefferies

1 Year Success Rate

1/3 ratings generated profit

1 Year Average Return

+3.30%

reiterated a buy rating a year ago

Copying Chris Lui's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +3.30% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing